

Marlen Castellanos-Fernandez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1142363/publications.pdf>

Version: 2024-02-01

12
papers

941
citations

1040056
9
h-index

1281871
11
g-index

12
all docs

12
docs citations

12
times ranked

1470
citing authors

#	ARTICLE	IF	CITATIONS
1	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 136-145.e6.	4.4	47
2	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology, 2021, 73, 2238-2250.	7.3	20
3	Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. Annals of Hepatology, 2021, 22, 100277.	1.5	12
4	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 65-72.	8.1	108
5	Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. Clinical and Experimental Hepatology, 2021, 7, 55-65.	1.3	1
6	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Annals of Hepatology, 2020, 19, 674-690.	1.5	72
7	Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. Current Therapeutic Research, 2020, 93, 100594.	1.2	1
8	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1625-1633.e1.	4.4	107
9	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology, 2018, 155, 443-457.e17.	1.3	536
10	Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba. Current Therapeutic Research, 2017, 85, 8-14.	1.2	2
11	HCV-specific immune responses induced by CIGB-230 in combination with IFN- α plus ribavirin. World Journal of Gastroenterology, 2014, 20, 148.	3.3	13
12	Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. Journal of Gene Medicine, 2010, 12, 107-116.	2.8	22